Adbry (tralokinumab-ldrm) Letter of Medical Necessity
Adbry (tralokinumab) is an IL-13 biologic for moderate-to-severe atopic dermatitis. Denials usually cite missing topical therapy history, missing severity scores, or a payer preference for Dupixent. A Letter of Medical Necessity that documents each point — and any reason dupilumab is unsuitable — usually reverses the denial.
FDA-Approved Indications
- ● moderate-to-severe atopic dermatitis in patients 12 years and older not adequately controlled with topical therapies
Why Adbry Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Topical corticosteroid and calcineurin inhibitor trials not documented
- 2. Baseline EASI, IGA, or BSA not on file
- 3. Preferred biologic (Dupixent) required first
- 4. Concurrent systemic immunosuppressant or JAK inhibitor
- 5. Dose escalation or quantity limit exceeded without justification
What to Include in a Adbry Letter of Medical Necessity
Record EASI, IGA, and BSA at baseline, and list topical corticosteroid and calcineurin inhibitor trials with potency, duration, and response. Document any prior dupilumab trial with outcome or adverse events (for example conjunctivitis), contraindications to JAK inhibitors, and the rationale for selective IL-13 inhibition.
Key clinical evidence to cite:
- ✓ ECZTRA 1 and 2 Phase 3 monotherapy trials — improved IGA 0/1 and EASI-75 vs placebo
- ✓ ECZTRA 3 — improved outcomes with concomitant topical corticosteroids
- ✓ Selective IL-13 targeting with a low rate of conjunctivitis in long-term extension data
Relevant guidelines:
- 📖 AAD 2023 Atopic Dermatitis Guidelines (Systemic Therapy)
- 📖 AAAAI/ACAAI 2023 AD Practice Parameter
Adbry Prior Authorization Criteria
Standard criteria across major US payers for Adbry. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Topical corticosteroid and calcineurin inhibitor trials not documented
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Adbry
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Adbry Prior Authorization FAQ
Why was my Adbry prior authorization denied?
The most common denial reasons for Adbry are: Topical corticosteroid and calcineurin inhibitor trials not documented; Baseline EASI, IGA, or BSA not on file; Preferred biologic (Dupixent) required first; Concurrent systemic immunosuppressant or JAK inhibitor; Dose escalation or quantity limit exceeded without justification.
What should a Adbry Letter of Medical Necessity include?
Record EASI, IGA, and BSA at baseline, and list topical corticosteroid and calcineurin inhibitor trials with potency, duration, and response. Document any prior dupilumab trial with outcome or adverse events (for example conjunctivitis), contraindications to JAK inhibitors, and the rationale for selective IL-13 inhibition.
Which payers cover Adbry?
Adbry is covered by major US payers including UnitedHealthcare, Aetna, Cigna, Anthem BCBS, Humana, Express Scripts, though formulary tier and prior authorization criteria vary.